Helicobacter pylori (H. pylori) infection is the principal cause of peptic ulcer disease, MALT lymphoma and non-cardia gastric cancer.
The major advances in diagnostics and treatment, eradication success are threatened by rising antimicrobial resistance and concerns about disruption of the normal microbiome. This review summarizes current unresolved issues in H.
pylori treatment, with a focus on resistance, optimal regimens, ecological impact, and emerging therapies.
Gastroenterology (AGA) published a clinical update in Research Highlights on 27 Mar 2026.
The item focuses on The Unfinished Agenda in Helicobacter pylori Treatment: Resistance, Microbiome Effects, and Future Directions.
Review the original article for the full source wording and details.